Compare IVVD & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVVD | SAR |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.1M | 372.7M |
| IPO Year | 2021 | N/A |
| Metric | IVVD | SAR |
|---|---|---|
| Price | $1.49 | $22.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | $8.75 | ★ $23.75 |
| AVG Volume (30 Days) | ★ 2.0M | 122.2K |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 14.89% |
| EPS Growth | ★ 79.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,426,000.00 | N/A |
| Revenue This Year | $143.48 | N/A |
| Revenue Next Year | $25.40 | $0.39 |
| P/E Ratio | ★ N/A | $9.44 |
| Revenue Growth | ★ 110.47 | N/A |
| 52 Week Low | $0.46 | $21.10 |
| 52 Week High | $3.07 | $25.64 |
| Indicator | IVVD | SAR |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 39.67 |
| Support Level | $1.41 | $21.40 |
| Resistance Level | $2.00 | $23.47 |
| Average True Range (ATR) | 0.13 | 0.55 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 18.55 | 21.66 |
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.